IL150822A0 - PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA - Google Patents

PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA

Info

Publication number
IL150822A0
IL150822A0 IL15082201A IL15082201A IL150822A0 IL 150822 A0 IL150822 A0 IL 150822A0 IL 15082201 A IL15082201 A IL 15082201A IL 15082201 A IL15082201 A IL 15082201A IL 150822 A0 IL150822 A0 IL 150822A0
Authority
IL
Israel
Prior art keywords
nhha
proteins
surface antigen
neisseria meningitidis
conserved regions
Prior art date
Application number
IL15082201A
Other languages
English (en)
Original Assignee
Univ Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Queensland filed Critical Univ Queensland
Publication of IL150822A0 publication Critical patent/IL150822A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL15082201A 2000-01-25 2001-01-25 PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA IL150822A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17791700P 2000-01-25 2000-01-25
PCT/AU2001/000069 WO2001055182A1 (fr) 2000-01-25 2001-01-25 PROTEINES COMPRENANT DES REGIONS CONSERVEES DE L'ANTIGENE DE SURFACE NEISSERIA MENINGITIDIS (NhhA)

Publications (1)

Publication Number Publication Date
IL150822A0 true IL150822A0 (en) 2003-02-12

Family

ID=22650445

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15082201A IL150822A0 (en) 2000-01-25 2001-01-25 PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA
IL150822A IL150822A (en) 2000-01-25 2002-07-18 Proteins Containing Preserved Areas of Meningitis Nisaria NhhA Area Antigens for Use as a Vaccine Against Multiple Strains of Meningitis Nisaria

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL150822A IL150822A (en) 2000-01-25 2002-07-18 Proteins Containing Preserved Areas of Meningitis Nisaria NhhA Area Antigens for Use as a Vaccine Against Multiple Strains of Meningitis Nisaria

Country Status (18)

Country Link
US (4) US7947291B2 (fr)
EP (2) EP2395013A3 (fr)
JP (3) JP2003523208A (fr)
KR (1) KR100698561B1 (fr)
CN (2) CN1419564A (fr)
AU (1) AU2818101A (fr)
BR (1) BR0107857A (fr)
CA (1) CA2398139A1 (fr)
CZ (1) CZ304379B6 (fr)
ES (1) ES2389719T3 (fr)
HU (1) HUP0300696A3 (fr)
IL (2) IL150822A0 (fr)
MX (1) MXPA02007184A (fr)
NO (1) NO332229B1 (fr)
NZ (1) NZ520445A (fr)
PL (1) PL216780B1 (fr)
WO (1) WO2001055182A1 (fr)
ZA (1) ZA200206153B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1979599A (en) * 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
EP2261352A3 (fr) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
JP2003518363A (ja) * 1999-04-30 2003-06-10 カイロン エセ．ピー．アー． 保存されたナイセリア抗原
EP2270173B1 (fr) * 1999-05-19 2016-01-06 GlaxoSmithKline Biologicals SA Compositions à base de combinaisons de Neisseria
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
PL216780B1 (pl) * 2000-01-25 2014-05-30 Univ Queensland Of Santa Lucia Wyizolowane białka zawierające konserwatywne obszary antygenu powierzchniowego NhhA z Neisseria meningitidis, białka fuzyjne, kompozycja farmaceutyczna, przeciwciało monoklonalne lub wiążący antygen fragment przeciwciała monoklonalnego, wyizolowany kwas nukleinowy, konstrukt ekspresyjny, komórka gospodarza, sposób wytwarzania rekombinowanego białka, sposób wykrywania N. meningitidis w próbce biologicznej, sposób diagnozowania zakażenia N. meningitidis oraz sposób wykrywania N. meningitidis w próbce biologicznej uzyskanej od pacjenta oraz zastosowanie wyizolowanego białka, białka fuzyjnego i konstruktu ekspresyjnego
ES2281409T3 (es) * 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
EP1524991A1 (fr) 2002-08-02 2005-04-27 GlaxoSmithKline Biologicals S.A. Composition de vaccin contenant des proteines de liaison a la transferrine et des hsf de bacteries gram negatif
GB0220199D0 (en) * 2002-08-30 2002-10-09 Univ Utrecht Mutant protein and refolding method
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
WO2007042326A2 (fr) * 2005-10-14 2007-04-19 Intercell Ag Antigenes de neisseria meningitidis
DE602007003596D1 (de) 2006-06-12 2010-01-14 Glaxosmithkline Biolog Sa Impfstoff
JP2012512240A (ja) 2008-12-17 2012-05-31 ノバルティス アーゲー ヘモグロビン受容体を含む髄膜炎菌ワクチン
HUE049695T2 (hu) 2009-03-24 2020-10-28 Glaxosmithkline Biologicals Sa Adjuváló H meningococcus faktort kötõ fehérje
EP3017826A1 (fr) 2009-03-24 2016-05-11 Novartis AG Combinaisons de protéines de liaison du facteur h méningococcique et de conjugués de saccharides de pneumocoques
US20110076300A1 (en) 2009-08-27 2011-03-31 Mariagrazia Pizza Hybrid Polypeptides Including Meningococcal fHBP Sequences
CN102740882A (zh) 2009-08-27 2012-10-17 诺华有限公司 含有铝、寡核苷酸和聚阳离子的佐剂
CN102724988B (zh) 2009-09-30 2014-09-10 诺华股份有限公司 脑膜炎球菌fHBP多肽的表达
CA2779816A1 (fr) 2009-10-27 2011-05-05 Novartis Ag Polypeptides fhbp meningococciques modifies
EP2544714A1 (fr) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Composition de vaccin
EP2545068B8 (fr) 2010-03-11 2018-03-21 GlaxoSmithKline Biologicals S.A. Composition immunogénique ou vaccin contre une infection ou maladie causée par des bacteries à gram-negatif, comme par exemple neisseria
CN102802662A (zh) 2010-03-18 2012-11-28 诺华有限公司 用于脑膜炎球菌血清组b的含佐剂疫苗
CA2803239A1 (fr) 2010-06-25 2011-12-29 Novartis Ag Associations de proteines de liaison du facteur h meningococcique
RU2013108881A (ru) * 2010-07-30 2014-09-10 Гриффит Юниверсити РЕКОМБИНАНТНЫЕ ПОРИНОВЫЕ БЕЛКИ Por A Neisseria meningitidis
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2012054879A1 (fr) * 2010-10-22 2012-04-26 Duke University Compositions et méthodes de traitement de l'arthrite purulente, de l'ostéomyélite et de la bactériémie
EP2707009A1 (fr) 2011-05-12 2014-03-19 Novartis AG Antipyrétiques pour améliorer la tolérabilité de vaccins à base de vésicules
EP2797624A1 (fr) 2011-12-29 2014-11-05 Novartis AG Combinaisons avec adjuvant de protéines méningococciques liant le facteur h
JP5957541B2 (ja) 2012-02-02 2016-07-27 ノバルティス アーゲー 髄膜炎菌における増加したタンパク質発現のためのプロモータ
JP2015517089A (ja) 2012-03-08 2015-06-18 ノバルティス アーゲー タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ
MX357538B (es) 2012-06-14 2018-07-13 Novartis Ag Vacunas para meningococo de serogrupo x.
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
JP6786394B2 (ja) 2014-02-28 2020-11-18 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変髄膜炎菌ｆＨｂｐポリペプチド
JP7165468B2 (ja) 2016-11-25 2022-11-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ｎＯＭＶ－抗原コンジュゲート及びその使用
BR112019010227A2 (pt) 2016-11-25 2019-10-08 Glaxosmithkline Biologicals S.A. conjugado imunogênico, processo para preparação de conjugado imunogênico, composição imunogênica, vacina, e, uso de nomv
CN121336262A (zh) * 2023-02-24 2026-01-13 百欧恩泰欧洲股份公司 用于工程化合成抗原以促进定制免疫反应的系统和方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849338A (en) 1982-07-16 1989-07-18 Syntex (U.S.A.) Inc. Simultaneous calibration heterogeneous immunoassay
US4843000A (en) 1979-12-26 1989-06-27 Syntex (U.S.A.) Inc. Simultaneous calibration heterogeneous immunoassay
US4550081A (en) 1980-05-19 1985-10-29 The Board Of Trustees Of The Leland Stanford Jr. University Non-reverting salmonella
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0273116A3 (fr) * 1986-10-09 1990-05-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Polypeptides des gonocoques et des méningocoques, vaccins et tests
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US5144847A (en) 1988-03-24 1992-09-08 Johann Zach Pressure or force measuring device
JP3436756B2 (ja) * 1988-12-19 2003-08-18 アメリカン・サイアナミド・カンパニー 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
AU649066B2 (en) 1990-07-25 1994-05-12 Syngene, Inc. Circular extension for generating multiple nucleic acid complements
US5422252A (en) 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US5646259A (en) 1995-03-24 1997-07-08 St. Louis University DNA encoding haemophilus adhesion proteins
AU714486B2 (en) 1995-11-21 2000-01-06 Yale University Unimolecular segment amplification and detection
GB9611673D0 (en) 1996-06-05 1996-08-07 Peptide Therapeutics Ltd Meningococcal vaccine
CN1263854C (zh) 1997-11-06 2006-07-12 启龙股份公司 奈瑟球菌抗原
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
AU1979599A (en) * 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
EP2261352A3 (fr) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
GB9810276D0 (en) * 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
WO2000061165A1 (fr) 1999-04-13 2000-10-19 Smithkline Beecham Corporation Motif d'adhesine conserve et ses procedes d'utilisation
JP2003518363A (ja) * 1999-04-30 2003-06-10 カイロン エセ．ピー．アー． 保存されたナイセリア抗原
CN101033467A (zh) * 1999-04-30 2007-09-12 希龙公司 奈瑟球菌基因组序列及其用法
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
PL216780B1 (pl) * 2000-01-25 2014-05-30 Univ Queensland Of Santa Lucia Wyizolowane białka zawierające konserwatywne obszary antygenu powierzchniowego NhhA z Neisseria meningitidis, białka fuzyjne, kompozycja farmaceutyczna, przeciwciało monoklonalne lub wiążący antygen fragment przeciwciała monoklonalnego, wyizolowany kwas nukleinowy, konstrukt ekspresyjny, komórka gospodarza, sposób wytwarzania rekombinowanego białka, sposób wykrywania N. meningitidis w próbce biologicznej, sposób diagnozowania zakażenia N. meningitidis oraz sposób wykrywania N. meningitidis w próbce biologicznej uzyskanej od pacjenta oraz zastosowanie wyizolowanego białka, białka fuzyjnego i konstruktu ekspresyjnego
EP1524991A1 (fr) * 2002-08-02 2005-04-27 GlaxoSmithKline Biologicals S.A. Composition de vaccin contenant des proteines de liaison a la transferrine et des hsf de bacteries gram negatif
EP1706481A2 (fr) * 2003-12-23 2006-10-04 GlaxoSmithKline Biologicals S.A. Vaccin

Also Published As

Publication number Publication date
NO20023487L (no) 2002-09-24
EP1252182A1 (fr) 2002-10-30
JP2003523208A (ja) 2003-08-05
EP1252182B1 (fr) 2012-06-20
ZA200206153B (en) 2003-11-03
NO332229B1 (no) 2012-08-06
EP2395013A3 (fr) 2012-03-21
MXPA02007184A (es) 2004-02-26
EP2395013A2 (fr) 2011-12-14
US8367070B2 (en) 2013-02-05
US20130136762A1 (en) 2013-05-30
NO20023487D0 (no) 2002-07-22
NZ520445A (en) 2004-02-27
US8383790B2 (en) 2013-02-26
HUP0300696A2 (hu) 2003-07-28
JP2012051902A (ja) 2012-03-15
ES2389719T3 (es) 2012-10-30
IL150822A (en) 2011-06-30
US20090068216A1 (en) 2009-03-12
US20020160016A1 (en) 2002-10-31
KR20020065938A (ko) 2002-08-14
CN102417537A (zh) 2012-04-18
KR100698561B1 (ko) 2007-03-21
US7947291B2 (en) 2011-05-24
JP2014024849A (ja) 2014-02-06
CN1419564A (zh) 2003-05-21
CZ304379B6 (cs) 2014-04-09
BR0107857A (pt) 2002-10-29
PL356819A1 (en) 2004-07-12
EP1252182A4 (fr) 2005-03-02
US20090068229A1 (en) 2009-03-12
WO2001055182A1 (fr) 2001-08-02
HUP0300696A3 (en) 2004-10-28
PL216780B1 (pl) 2014-05-30
AU2818101A (en) 2001-08-07
CA2398139A1 (fr) 2001-08-02
CZ20022482A3 (cs) 2003-01-15

Similar Documents

Publication Publication Date Title
HUP0300696A3 (en) Proteins comprising conserved regions of neisseria meningitidis surface antigen nhha
IL136684A0 (en) Novel surface protein of neisseria meningitidis
IL151942A0 (en) Compositions and methods for enhancing immunogenicity of antigens
HUP0204250A3 (en) Use of hiv-protein or -polynucleotide for vaccine produce
CY2011001I1 (el) Εμβολια συνδυασμου για neisseria meningitidis
IL212419A0 (en) Methods of administering anti-tnf antibodies
TW479494U (en) Structure of pillow
AU7573901A (en) Method of producing functional protein domains
HUP0300099A3 (en) Vaccine for the treatment of artherosclerosis
EP1428828A4 (fr) Procede de preparation d'alkoxysilanes
IL154301A0 (en) Purification of hbv antigens for use in vaccines
PL367329A1 (en) Methods for reducing immunogenicity of polypeptides
FR2809615B3 (fr) Appareil electromecanique pour assurer le mouvement de flexion/extension des membres inferieurs chez les patients presentant une diminution des fonctions superieures
AU2001267613A1 (en) Adjuvant composition comprising FHA protein or fragment of FHA protein in free form
GB0105606D0 (en) Immunogens and vaccines and their preparation and use
TW567810U (en) Massage pillow
TW492296U (en) Multifunctional pillow for children
TW435705U (en) Glasses foot of eyeglasses
GB0031218D0 (en) Metgod of vaccine preparation
TW496157U (en) Massage chair
TW457913U (en) Construction of disposable pulp-molded pillow
TW435704U (en) Structure improvement of glasses foot for eyeglasses
GB0130306D0 (en) Method of vaccine preparation
ZA200400228B (en) Therapeutic agents comprising pro-apoptotic proteins
TW557772U (en) Improved structure of pillow